Aardvark Therapeutics, Inc.
No SEC Form 4 filings for $AARD in the last 30 days.
See all $AARD insider activity →Aardvark Therapeutics (AARD) shares rose 11.1% in pre-open after the company reported Q2 2026 results on Aug. 11. According to the article, EPS beat expectations by $0.21 versus consensus of -$0.88. Aardvark reported $73.9M cash and said it remains in active FDA discussions to resolve the ARD-101 clinical hold.
Aardvark Therapeutics, Inc. (AARD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ck0001774857-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates Assessing unblinded Phase 3 HERO and OLE data for ARD-101 in PWS in the third quarter of 2026 to support an informed de
Hagens Berman said Aardvark Therapeutics’ (NASDAQ: AARD) shares fell $2.16, or 32%, on May 15, 2026 after the FDA placed a clinical hold on the company’s ARD-101 program for Prader-Willi syndrome. It also cited a March 2 2026 drop of $7.02, or 56%, after Aardvark paused its Phase 3 HERO trial. The firm is investigating Aardvark’s disclosures and FDA communications.
Over the past 7 days, alphai's AI scored 2 news stories mentioning AARD (Aardvark Therapeutics, Inc.). Coverage has been balanced: 1 bullish, 0 neutral, and 1 bearish.
Recent AARD coverage spans financial news, earnings and regulation.
The earnings beat plus an extended cash runway and renewed FDA dialogue are near-term catalysts that can sustain momentum and reduce financing risk.
Clinical hold and trial termination materially increase regulatory and development risk for ARD-101, while cash runway extends only to late 2027.
FDA clinical hold materially increases development risk and likely extends timelines, keeping downside pressure on the stock until clarity on hold resolution emerges.
The filing is a corporate/compensation update that may signal management retention priorities but does not change clinical or financial guidance.
The FDA clinical hold and increased regulatory hurdles significantly threaten Aardvark Therapeutics' near-term prospects, leading to a bearish outlook. The company's lead program, ARD-101, faces delays, and competitive pressures from other treatments for Prader-Willi syndrome add to the challenges.
alphai scores every news story that mentions AARD with an AI model for sentiment and relevance, and aggregates insider trades from Aardvark Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Aardvark Therapeutics (AARD) shares rose 11.1% in pre-open after the company reported Q2 2026 results on Aug. 11. According to the article, EPS beat expectations by $0.21 versus consensus of -$0.88. Aardvark reported $73.9M cash and said it remains in active FDA discussions to resolve the ARD-101 clinical hold.
4 min readAardvark Therapeutics, Inc. (AARD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ck0001774857-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates Assessing unblinded Phase 3 HERO and OLE data for ARD-101 in PWS in the third quarter of 2026 to support an informed de
4 min readHagens Berman said Aardvark Therapeutics’ (NASDAQ: AARD) shares fell $2.16, or 32%, on May 15, 2026 after the FDA placed a clinical hold on the company’s ARD-101 program for Prader-Willi syndrome. It also cited a March 2 2026 drop of $7.02, or 56%, after Aardvark paused its Phase 3 HERO trial. The firm is investigating Aardvark’s disclosures and FDA communications.
4 min readAardvark Therapeutics, Inc. (AARD) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001774857 0001774857 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10,
3 min readBank of America Securities analyst Tazeen Ahmad downgraded Aardvark Therapeutics to a Sell rating and slashed its price target from $18 to $4. This downgrade is due to an FDA clinical hold on the company's lead program, ARD-101, following cardiac issues in trials. Increased regulatory hurdles and growing competition from other treatments for Prader-Willi syndrome also contributed to the revised outlook.
2 min readAardvark Therapeutics announced that the FDA has placed a full clinical hold on its investigational new drug application (IND) for ARD-101, impacting its Phase 3 HERO trial and open-label extension trial for Prader-Willi Syndrome. The company plans to unblind clinical data from both trials to inform the next steps for its ARD-101 program while engaging with the FDA to resolve the hold. Aardvark currently has $91.2 million in cash equivalents, which is expected to fund operations into mid-2027.
4 min readMorgan Stanley downgraded Aardvark Therapeutics (NASDAQ:AARD) from Overweight to Equalweight and cut its price target to $7.00 from $29.00 following the company's voluntary pause of its Phase 3 HERO trial due to reversible cardiac observations in a healthy volunteer study. Despite other firms like B.Riley and Raymond James maintaining positive ratings, RBC Capital also downgraded the stock, reflecting increased uncertainty regarding the drug's path forward. The company, currently trading down 72% from its 52-week high, plans to meet with the FDA and provide an update in Q2 2026.
4 min readAardvark Therapeutics (NASDAQ:AARD) saw its stock increase by approximately 13% after announcing positive developments in its clinical programs, including the first patient dosed in the Phase 3 HERO trial in Australia and a high enrollment rate in its open-label extension study. BTIG analyst Jeet Mukherjee maintained a Buy rating and a $26.00 price target, citing promising safety and efficacy signals. The company maintains financial flexibility with more cash than debt, and topline data for the trial is anticipated in Q3 2026.
4 min readSAN DIEGO, Nov. 17, 2025 ( GLOBE NEWSWIRE ) -- Artisan Therapeutics, Inc. ( "Artisan" ) and Tulex Pharmaceuticals ( "Tulex" ) today announced encouraging Phase 2a clinical results highlighting the potential of ART-501 for the treatment of autism spectrum disorder ( "ASD" ) -related conditions.
3 min readSAN DIEGO, Nov. 11, 2025 ( GLOBE NEWSWIRE ) -- Aardvark Therapeutics, Inc. ( Aardvark ) ( Nasdaq: AARD ) , a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today ...
2 min read
